In this presentation, Dr. John Vetto, MD, FACS shares why more than 56,000 DecisionDx-Melanoma tests have been ordered to better inform management plan decisions surrounding Stage I-III melanoma patients.

Approximately 88% of patients who undergo the SLNB surgical procedure will have a negative result and derive little to no benefit from the procedure.

DecisionDx-Melanoma, a molecular diagnostic test for melanoma, provides actionable information, independent of traditional staging factors with significant risk stratification for patients with Class 1A (low risk) and Class 2B (high risk) results. These test results assist in improving patient selection for the SLNB procedure by identifying those with sufficient low risk of a positive node, thus avoiding the procedure.

Did you know?

• DecisionDx-Melanoma impacts clinical management decisions for 1 in 2 patients.
• DecisionDx-Melanoma can improve SLNB patient selection by identifying biologically low-risk disease among SLNB-eligible patients with T1-T2 tumors.
• In a combined cohort of 3,093 patients, DecisionDx-Melanoma is validated for identifying those at low risk for a positive SLN.
• More than 20 peer reviewed publications show consistent findings in over 5,700 patients across multiple validation, prospective and clinical impact studies.
• DecisionDx-Melanoma is a strong, independent predictor of melanoma-specific survival.